Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada
by Zacks Equity Research
Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.
AstraZeneca's (AZN) sBLA for New Imfinzi Dosage Gets Approval
by Zacks Equity Research
AstraZeneca's (AZN) Imfizni is now available in monthly, fixed-dose regimen as alternative to twice-monthly, weight-based regimen for all three approved indications.
Gilead (GILD) Down on COVID-19 Drug Remdesivir Update
by Zacks Equity Research
Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.
Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.
Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate
by Zacks Equity Research
Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.
Should Value Investors Choose Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.
Biotech Stock Roundup: MRNA's Progress With Coronavirus Vaccine, News From BMY, ALKS
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and Bristol Myers (BMY) among others provide updates.
Glaxo (GSK) Candidate Gets Breakthrough Tag for HIV Prevention
by Zacks Equity Research
FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.
Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study
by Zacks Equity Research
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
TEVA Posts In-Line Q3 Earnings, Lowers Sales View, Stock Down
by Zacks Equity Research
TEVA's earnings match estimates while sales miss the same for third-quarter 2020. It lowers its previously issued sales guidance for 2020. Stock down.
How Will Biotech ETFs React to These Q3 Earnings Release?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their third-quarter earnings releases amid the coronavirus crisis.
Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More
by Zacks Equity Research
Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.
Ligand (LGND) Q3 Earnings & Sales Fall Short of Estimates
by Zacks Equity Research
Ligand (LGND) reports lower-than-expected third-quarter 2020 earnings and revenues. Outlook for 2020 & 2021 also are below expectations. Stock down.
The Zacks Analyst Blog Highlights: Pinterest, Etsy, Gilead and Ford
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pinterest, Etsy, Gilead and Ford
Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.
Update on the COVID Vaccine Race
by John Blank
A 2021 Macro Recovery is About This, Alone.
Gilead Sciences (GILD) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 15.30% and 6.07%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Halloween Nightmare Market Close: Q3 Reports for PINS, ETSY, GILD & F
by Mark Vickery
The Nasdaq led the way down, -3.7% or 426 points; the S&P 500 dropped 3.5% or 120 points; and the Dow, just off session lows at the end of the normal trading day, fell 3.4% or 943 points.
What's in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Higher Captisol sales to support availability of Gilead's COVID-19 treatment, remdisivir, is expected to have driven Ligand's (LGND) revenues in the third quarter.
Biotech Stock Roundup: GILD's Veklury Approved, NVAX Provides Vaccine Update & More
by Zacks Equity Research
Gilead (GILD) and Novavax (NVAX) continue to be in the spotlight on coronavirus-related updates.
Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More
by Zacks Equity Research
Let us take a look at four drug/biotech companies due to release their quarterly results on Oct 28.